Xn:Harmful;17227-47-3Relevant articles and documents
Discovery of New 4-Indolyl Quinazoline Derivatives as Highly Potent and Orally Bioavailable P-Glycoprotein Inhibitors
Chen, Zhe-Sheng,Dai, Qing-Qing,Li, Guo-Bo,Liu, Hong-Min,Liu, Hui,Wang, Bo,Wang, Shaomeng,Yu, Bin,Yuan, Shuo,Zhang, Jing-Ya,Zhang, Xiao-Nan,Zuo, Jia-Hui
, p. 14895 - 14911 (2021/10/12)
The major drawbacks of P-glycoprotein (P-gp) inhibitors at the clinical stage make the development of new P-gp inhibitors challenging and desirable. In this study, we reported our structure-activity relationship studies of 4-indolyl quinazoline, which led to the discovery of a highly effective and orally active P-gp inhibitor, YS-370. YS-370 effectively reversed multidrug resistance (MDR) to paclitaxel and colchicine in SW620/AD300 and HEK293T-ABCB1 cells. YS-370 bound directly to P-gp, did not alter expression or subcellular localization of P-gp in SW620/AD300 cells, but increased the intracellular accumulation of paclitaxel. Furthermore, YS-370 stimulated the P-gp ATPase activity and had moderate inhibition against CYP3A4. Significantly, oral administration of YS-370 in combination with paclitaxel achieved much stronger antitumor activity in a xenograft model bearing SW620/Ad300 cells than either drug alone. Taken together, our data demonstrate that YS-370 is a promising P-gp inhibitor capable of overcoming MDR and represents a unique scaffold for the development of new P-gp inhibitors.
Design, Synthesis, Antiviral Activities of Novel Phosphonate Derivatives Containing Quinazoline Based on Chalone Motif
Zhang, Guo-Ping,Pan, Jian-Ke,Zhang, Jian,Wu, Zeng-Xue,Liu, Deng-Yue,Zhao, Lei
, p. 2548 - 2555 (2017/07/25)
Based on the structure of natural product chalone, a series of novel phosphonate derivatives were designed and synthesized through 1,4-hydrophosphinylation of α,β-unsaturated carbonyl compounds. Their structures were characterized by IR, NMR, MS, and elemental analysis. The antiviral activities against cucumber mosaic virus were evaluated for the first time. The bioassay results indicated that most compounds exhibited good protective activities, low curative activities, and weak inactive activities. The antiviral protective activities of compounds C2 and C5 were 55.1% and 56.8%, respectively, which are slightly higher than those of the commercial Ningnanmyin (49.3%) and Dufulin (53.1%). Moreover, compounds C2 and C9 exhibited moderate curative activities (42.6% and 46.6%). Therefore, the basic motif of C1 can be used as a new lead structure for developing antivirus agents.
COMPOUND HAVING TGF-BETA INHIBITORY ACTIVITY AND PHARMACEUTICAL COMPOSITION CONTAINING SAME
-
Page/Page column 48, (2010/11/24)
The present invention provides compounds of formula (I) or compounds of formula (II) and pharmaceutically acceptable salts or solvates thereof. An objective of the present invention is to provide compounds having TGF2 inhibitory activity.
